PETN, ISDN
PreclinicalSmall molecule
PETN, ISDN is one of 7 small molecule programs targeting Endothelial Function. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Endothelial Function
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Nulojix
Bristol-Myers SquibbApproved
Azulfidine
PfizerPreclinical
Slow Sodium
SSt George's, University of London
Preclinical
Viagra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
PETN, ISDN
JJulius-Maximilians University
Preclinical
L-NG-Monomethyl Arginine (l-NMMA)
EEmory University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PETN, ISDN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- JJulius-Maximilians University